Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2250)	3/24/2008 4:57:14 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AUXL was up 13.61% on volume of 1,498,686 above its ADV The stock is trying to get off its near term DT coming from its Feb 12 H at $36.14 bigcharts.marketwatch.com One "analyst" upgraded the stock to "Buy" from "Hold," saying that he expects positive data on its PIII of Xiaflex,but another "analyst" downgraded the stock to "Sell" from "Neutral" , saying that the evidence linking the drug to tendon ruptures could delay the approval and launch of the drug. Xiaflex treats Dupuytren's contracture,which some claim is somewhat more prevalent among diabetics,although it isn't uncommon on elderly people which have suffered from some chronic trauma to the flexor tendons of the hand, albeit the ultimate etiology is not known. AUXL has 4Qs of double digit improvement on revenues, which have also increased on a sequential basis, & has been trimming its losses, but the EL for 2008 is still around $1.10 The Feb H was an all time H bigcharts.marketwatch.com Bernard